Rosen Law Firm Investigates Aardvark Therapeutics Securities Fraud Claims

Rosen Law Firm announced it is investigating Aardvark Therapeutics, Inc. (NASDAQ: AARD) for potential securities fraud. The investigation focuses on alleged violations of federal and state securities laws, specifically concerning purchasers of the company's common stock.

The law firm is seeking investors who have sustained losses of $100,000 or more in connection with their Aardvark Therapeutics stock purchases. These purchases are reportedly linked to the company's registration statement and prospectus.

Rosen Law Firm, which describes itself as a global investor rights firm, is encouraging affected investors to contact them. The firm has a history of prosecuting securities class actions on behalf of investors.

Further details regarding the specific nature of the alleged fraud and the timeline of the investigation were not immediately available. The firm has set a deadline for investors to participate in the potential lawsuit.